Alvotech enters into commercialization agreement with advanz pharma for proposed biosimilar to xolair® (omalizumab)

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with advanz pharma, for the commercialization of avt23, a proposed biosimilar to xolair® (omalizumab).  the agreement covers the european economic area, uk, switzerland, canada, australia and new zealand.
ALVO Ratings Summary
ALVO Quant Ranking